Literature DB >> 9517954

Effect of terbinafine on theophylline pharmacokinetics in healthy volunteers.

E F Trépanier1, A N Nafziger, G W Amsden.   

Abstract

Twelve healthy volunteers were enrolled in an open-label, randomized, crossover study. Subjects received single doses of theophylline (5 mg/kg) with and without multiple-dose terbinafine, and 11 blood samples were collected over 24 h. The study phases were separated by a 4-week washout period. Theophylline serum data were modeled via noncompartmental analysis. When the control phase (i.e., no terbinafine) was compared to the treatment phase (terbinafine), theophylline exposure (the area under the serum concentration-time curve from time zero to infinity) increased by 16% (P = 0.03), oral clearance decreased by 14% (P = 0.04), and half-life increased by 24% (P = 0.002). No significant changes in other theophylline pharmacokinetic parameters were evident.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9517954      PMCID: PMC105520     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  13 in total

1.  Prediction of creatinine clearance from serum creatinine.

Authors:  D W Cockcroft; M H Gault
Journal:  Nephron       Date:  1976       Impact factor: 2.847

2.  Terbinafine for onychomycosis.

Authors: 
Journal:  Med Lett Drugs Ther       Date:  1996-08-16       Impact factor: 1.909

3.  Effect of ketoconazole and terbinafine on the pharmacokinetics of caffeine in healthy volunteers.

Authors:  A Wahlländer; G Paumgartner
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

4.  TopFit: a PC-based pharmacokinetic/pharmacodynamic data analysis program.

Authors:  P Tanswell; J Koup
Journal:  Int J Clin Pharmacol Ther Toxicol       Date:  1993-10

Review 5.  Theophylline in asthma.

Authors:  M Weinberger; L Hendeles
Journal:  N Engl J Med       Date:  1996-05-23       Impact factor: 91.245

Review 6.  The use of caffeine for enzyme assays: a critical appraisal.

Authors:  W Kalow; B K Tang
Journal:  Clin Pharmacol Ther       Date:  1993-05       Impact factor: 6.875

7.  The interaction of representative members from two classes of antimycotics--the azoles and the allylamines--with cytochromes P-450 in steroidogenic tissues and liver.

Authors:  I Schuster
Journal:  Xenobiotica       Date:  1985-06       Impact factor: 1.908

Review 8.  Influence of endogenous and exogenous effectors on the pharmacokinetics of theophylline. Focus on biotransformation.

Authors:  U Tröger; F P Meyer
Journal:  Clin Pharmacokinet       Date:  1995-04       Impact factor: 6.447

Review 9.  Terbinafine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial mycoses.

Authors:  J A Balfour; D Faulds
Journal:  Drugs       Date:  1992-02       Impact factor: 9.546

10.  Gender differences in hepatic induction and inhibition of theophylline pharmacokinetics and metabolism.

Authors:  T S Jennings; A N Nafziger; L Davidson; J S Bertino
Journal:  J Lab Clin Med       Date:  1993-08
View more
  6 in total

Review 1.  Effects of the antifungal agents on oxidative drug metabolism: clinical relevance.

Authors:  K Venkatakrishnan; L L von Moltke; D J Greenblatt
Journal:  Clin Pharmacokinet       Date:  2000-02       Impact factor: 6.447

Review 2.  A risk-benefit assessment of the newer oral antifungal agents used to treat onychomycosis.

Authors:  A K Gupta; N H Shear
Journal:  Drug Saf       Date:  2000-01       Impact factor: 5.606

3.  Quantitative Prediction of Drug Interactions Caused by CYP1A2 Inhibitors and Inducers.

Authors:  Laurence Gabriel; Michel Tod; Sylvain Goutelle
Journal:  Clin Pharmacokinet       Date:  2016-08       Impact factor: 6.447

Review 4.  Pharmacokinetics of antifungal agents in onychomycoses.

Authors:  D Debruyne; A Coquerel
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

Review 5.  Terbinafine. An update of its use in superficial mycoses.

Authors:  K J McClellan; L R Wiseman; A Markham
Journal:  Drugs       Date:  1999-07       Impact factor: 9.546

6.  Population PBPK modeling using parametric and nonparametric methods of the Simcyp Simulator, and Bayesian samplers.

Authors:  Janak R Wedagedera; Anthonia Afuape; Siri Kalyan Chirumamilla; Hiroshi Momiji; Robert Leary; Mike Dunlavey; Richard Matthews; Khaled Abduljalil; Masoud Jamei; Frederic Y Bois
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2022-04-22
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.